• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Pembrolizumab versus Nivolumab–Ipilimumab for Treatment-Naive Advanced Non-Small-Cell Lung Cancer

byAstrid BradshawandAlisha Yi
September 4, 2024
in StudyGraphics
Reading Time: 1 min read
0
Share on FacebookShare on Twitter

Click here to read this study in the Lancet.

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

2 Minute Medicine Rewind June 8, 2026

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

Tags: adjuvant pembrolizumabadjuvant therapy for NSCLClung cancernivolumab-ipilimumabnon-small cell lung cancernon-small cell lung cancer (NSCLC)non-small cell lung cancer treatmentnsclcPembrolizumab
Previous Post

BioNTech’s mRNA Cancer Candidate Packs A Punch With Regeneron’s Cemiplimab In Phase 2 Melanoma Trial

Next Post

Intravenous amino acids decrease acute kidney injury following cardiac surgery

RelatedReports

Lessons from real-world implementation of lung cancer screening
Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026
Weekly Rewinds

2 Minute Medicine Rewind June 8, 2026

June 8, 2026
Preoperative bilateral breast imaging may reduce contralateral cancer recurrence
Oncology

Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer

January 28, 2026
Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Oncology

Positive lung cancer screens frequently receive suboptimal follow-up

December 15, 2025
Next Post

Intravenous amino acids decrease acute kidney injury following cardiac surgery

Oseltamivir and peramivir may reduce length-of-hospital-stay in patients with severe influenza

Epileptogenic foci may be lateralized using functional brain glutamate imaging

Liberal transfusion strategy does not improve post-traumatic brain injury neurologic outcomes

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • High intake of sugar-sweetened beverages is associated with increased risk of hepatocellular carcinoma
  • Pediatric hospitals adopt generative AI for documentation and care coordination
  • Hospitals face a new test of artificial intelligence governance
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.